CSPC's JMT108 receives clinical trial approval in China

CSPC Pharmaceutical Group Limited (HKEX: 1093) announced that its new Class I bi-functional fusion protein drug, JMT108, has been approved by the National Medical Products Administration of the People's Republic of China. The approval allows CSPC to conduct clinical trials with JMT108 in China. JMT108 is a recombinant, fully human anti-PD-1/IL-15 bi-functional fusion protein designed to relieve immunosuppression on PD-1 positive tumor infiltrating immune cells and enhance anti-tumor efficacy. Preclinical studies have indicated that JMT108 has a broad variety of indications with significant anti-tumor effects and a good safety profile in multiple malignant tumor models, providing a promising clinical development value.